Post by sshl on Nov 10, 2017 15:34:15 GMT
hey drangled.... I looked into sanuwave and have a few questions. There is an amazing amount of debt. There is very little cash left in the coiffer. Inventories and cash on hand are decreasing at a very strong rate. as stated in the last earnings report : "The Company does not currently generate significant recurring revenue and will require additional capital during the third quarter of 2017. As of June 30, 2017, the Company had an accumulated deficit of $101,342,917 and cash and cash equivalents of $62,069. For the six months ended June 30, 2017 and 2016, the net cash used by operating activities was $572,492 and $1,731,124, respectively. The Company incurred a net loss of $1,909,469 for the six months ended June 30, 2017 and a net loss of $6,439,040 for the year ended December 31, 2016. The operating losses create an uncertainty about the Company’s ability to continue as a going concern."
This line also caught my attention as familiar to the situation I experience as a COCP investor :"The continuation of the Company’s business is dependent upon raising additional capital during the third quarter of 2017 to fund operations. Management’s plans are to obtain additional capital in 2017 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, the issuance of common or preferred stock."
The two things I see as a positives ( and I know my limitations on reading and understanding reports) are the completion of the phase lll trials of its derma pace device and the application for approval in the US and the deal with Brazil's Mundimed - SANUWAVE Health announced today they have signed a binding definitive joint venture agreement with MUNDIMED in Brazil. The companies will split profits in the wound care arena while utilizing the dermaPACE® . which they assume may create $25 mil in revenue.
Am I missing any other relative infomation ?
This line also caught my attention as familiar to the situation I experience as a COCP investor :"The continuation of the Company’s business is dependent upon raising additional capital during the third quarter of 2017 to fund operations. Management’s plans are to obtain additional capital in 2017 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, the issuance of common or preferred stock."
The two things I see as a positives ( and I know my limitations on reading and understanding reports) are the completion of the phase lll trials of its derma pace device and the application for approval in the US and the deal with Brazil's Mundimed - SANUWAVE Health announced today they have signed a binding definitive joint venture agreement with MUNDIMED in Brazil. The companies will split profits in the wound care arena while utilizing the dermaPACE® . which they assume may create $25 mil in revenue.
Am I missing any other relative infomation ?